Table 4.

Frequency of treatment emergent adverse events (all causalities)

XG-102 dose	Placebo	10 μg/kg	40 μg/kg	80 μg/kg
Number of subjects treated	6	6	6	6
MedDRA Preferred Term by System Organ Class	Number of subjects with adverse events [number of adverse events]
Nervous system disorders
Headache	2 [2]		3 [3]
Total	2 [2]		3 [3]
Gastrointestinal disorders
Diarrhea		2 [2]
Nausea			1 [1]
Total		2 [2]	1 [1]
General disorders and administration site conditions
Fatigue				1 [1]
Local swelling				1 [1]
Total				2 [2]
Ear and labyrinth disorders
Otitis media		1 [1]
Total		1 [1]
Infection and Infestations
Nasopharyngitis	1 [1]
Total	1 [1]
Injury, poisoning, and procedural complications
Contusion		1 [1]
Total		1 [1]
Respiratory, thoracic and mediastinal disorders
Chest pain			1 [1]
Total			1 [1]
Skin injuries
Laceration		1 [1]
Total		1 [1]
Vascular disorders
Hematoma				1 [1]
Total				1 [1]
Overall total	2 [3]	3 [5]	4 [5]	2 [3]